February 15, 2018
The business of bioanalysis: unique panel discussion from expert pharmaceutical and CRO professionals
Bioanalysis Zone showcases season two of the business of bioanalysis; a unique panel discussion series featuring key experts from the pharmaceutical and CRO industries, offering perspectives on current issues in the field of bioanalysis.
Bioanalysis Zone is delighted to showcase season two of the video panel discussion series, the business of bioanalysis, filmed in Barcelona, Spain.
Chaired by Neil Spooner, Senior Editor of Future Science Group’s Bioanalysis journal, this panel discussion focuses on the key business challenges within bioanalysis. The panel comprises leading CRO and pharmaceutical professionals: Chris Beaver (InVentiv Health), John Kolman (QPS), Scott Summerfield (GlaxoSmithKline), Liz Thomas (Alderley Analytical), Tom Verhaeghe (Johnson & Johnson) and Amanda Wilson (AstraZeneca).
Published in three parts exclusively on Bioanalysis Zone, the first video in the series addresses the issue of outsourcing and the priorities that must be considered when making a purchasing decision. Panelists review data from a Bioanalysis Zone outsourcing survey highlighting that 75% of pharmaceutical companies consider cost the most important priority for outsourcing.
In the subsequent videos, the panelists go on to share their perspectives on the current gaps in regulations and what new technologies need to emerge to overcome current issues in bioanalysis.
Naamah Maundrell, Editor of Bioanalysis Zone commented: “We are delighted to present season two of these videos to the community. This exclusive three-part panel discussion enables CROs and pharma to have open conversations about the key issues affecting them in the industry. Panelists raised crucial questions about patient centric sampling and how easy it will be to regulate and also about regulations, suggesting that more flexible guidelines could allow scientists to interpret and apply the regulations to new technologies. We hope you enjoy watching the discussions.”
Bioanalysis Zone would also like to take this opportunity to thank the panelists, as well as the sponsors of this series, without whom the panel event would not be possible; InVentiv Health and QPS.
The series of discussion videos are available to watch now at: https://www.bioanalysis-zone.com/2018/01/23/business-of-bioanalysis-season-2_bob2/
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 9,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.